Events

Upcoming Events

American Society of Clinical Oncology (ASCO) Annual Meeting

June 5, 2016, 8:00 AM - 11:30 AM CDT — Chicago, IL

Aung Naing, M.D., Associate Professor, Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center: Clinical activity and safety of PEGylated human IL-10 (AM0010) in combination with anti-PD1
Kyriakos Papadopoulos, M.D., Senior Clinical Investigator at START Center for Cancer Care: Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with pancreatic or colorectal cancer
Details

Past Events

AACR Annual Meeting

April 19, 2016, 10:30 AM - 12:15 PM EDT — New Orleans, LA

Jeffrey Infante, M.D., Director, Drug Development Program and Principal Investigator, Sarah Cannon Research Institute: Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with advanced solid tumors

Jefferies Immuno-Oncology Summit

April 8, 2016, 11:50 AM - 12:15 PM EDT — Boston, MA

Peter Van Vlasselaer, PhD, President and CEO

3rd Immunotherapy of Cancer Conference (ITOC3) – The Cancer Drug Development Forum

March 22, 2016, 12:20 - 12:35 pm Central European Time — Munich, Germany

Martin Oft, MD: Safety, immune activation and anti-tumor efficacy of PEGylated recombinant human IL-10 (AM0010) in patients with advanced solid tumors – a Phase 1 study

Cowen and Company 36th Annual Health Care Conference

March 9, 2016, 9:00 AM - 9:25 AM EST — Boston, MA

Peter Van Vlasselaer, PhD, President and CEO

Leerink Partners 5th Annual Global Healthcare Conference

February 11, 2016, 1:25 PM - 1:45 PM EST — New York, NY

Peter Van Vlasselaer, PhD, President and CEO

A live audio webcast of the presentation can be accessed at http://wsw.com/webcast/leerink26/armo. A replay will be available for 14 days following the presentation.

34th Annual J.P. Morgan HealthCare Conference

January 12, 2016, 3:00 PM - 3:25 PM PST — San Francisco, CA

Peter Van Vlasselaer, PhD, President and CEO

ESMO Symposium on Immuno-Oncology 2015

November 20-21, 2015 — Lausanne, Switzerland

Martin Oft, MD: PEGylated recombinant human IL-10 (AM0010) for advanced solid tumors - a Phase 1 study

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

November 5-9, 2015 — Boston, MA

PEGylated recombinant human IL-10 (AM0010) for advanced solid tumors - a Phase 1 study

Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting & Associated Programs

November 4-8, 2015 — National Harbor, MD

PEGylated recombinant human IL-10 (AM0010) for advanced solid tumors - a Phase 1 study

Bio Investor Forum

October 20-21, 2015 — San Francisco, CA

Peter Van Vlasselaer, PhD, President and CEO

CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference, Translating Science into Survival 2015

September 16-19, 2015 — New York, NY

Martin Oft, MD: PEGylated recombinant human IL-10 (AM0010) for advanced solid tumors - a Phase 1 study